...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Co-delivery of doxorubicin and I-131 by thermosensitive micellar-hydrogel for enhanced in situ synergetic chemoradiotherapy
【24h】

Co-delivery of doxorubicin and I-131 by thermosensitive micellar-hydrogel for enhanced in situ synergetic chemoradiotherapy

机译:热敏胶束-水凝胶共同递送阿霉素和I-131,以增强原位协同放化疗

获取原文
获取原文并翻译 | 示例
           

摘要

Combined chemoradiotherapy is potent to defeat malignant tumor. Concurrent delivery of radioisotope with chemotherapeutic drugs, which also act as the radiosensitizer, to tumor tissues by a single vehicle is essential to achieve this objective. To this end, a macroscale injectable and thermosensitive micellar-hydrogel (MHg) depot was constructed by thermo-induced self-aggregation of poly(epsilon-caprolactone-co-1,4,8-trioxa[4.6]spiro-9-undecanone)-poly(ethyleneglycol)-poly(epsilon-caprolactone-co-1,4,8-trioxa[4.6]spiro-9-undecanone) (PECT) triblock copolymer micelles (Ms), which could not only serve as a micellar drug reservoir to locally deliver concentrated nano chemotherapeutic drugs, but also immobilize radioisotopes at the internal irradiation hot focus. Doxorubicin (DOX) and iodine-131 labeled hyaluronic acid (I-131-HA) were used as the model therapeutic agents. The aqueous mixture of drug-loaded PECT micelles and I-131-HA exhibited sol-to-gel transition around body temperature. In vitro drug release study indicated that PECT/DOX Ms were sustainedly shed from the native PECT/DOX MHg formulation, which could be internalized by tumor cells with rapid intracellular DOX release. This hydrogel formulation demonstrated considerable in vitro antitumor effect as well as remarkable radiosensitization. In vivo subcutaneous injection of PECT MHg demonstrated that I-131 isotope was immobilized stably at the injection location and no obvious indication of damage to major organs were observed as indicated by the histopathological analysis. Furthermore, the peritumoral injection of chemo-radiation therapeutic agents-encapsulated MHg formulation on tumor-bearing nude mice resulted in the desired combined treatment effect, which significantly improved the tumor growth inhibition efficiency with minimized drug-associated side effects to major organs. Consequently, such a thermosensitive MHg formulation, which enabled the precise control over the dosage and ratio of combination therapeutic agents to obtain the desired therapeutic effect with a single drug administration and reduced side effects, holds great potential for spatiotemporally delivery of multiple bioactive agents for sustained combination therapy. (C) 2015 Elsevier B.V. All rights reserved.
机译:联合放化疗对消除恶性肿瘤有效。通过单一媒介将放射性同位素与也可作为放射增敏剂的化学治疗药物同时递送至肿瘤组织对于实现该目标至关重要。为此,通过热诱导聚(ε-己内酯-co-1,4,8-三恶英[4.6] spiro-9-十一烯酮)的自聚集来构建大规模可注射且热敏的胶束-水凝胶(MHg)库。 -聚(乙二醇)-聚(ε-己内酯-co-1,4,8-三恶[4.6] spiro-9-十一烷酮)(PECT)三嵌段共聚物胶束(Ms),它不仅可以用作胶束药物库局部递送浓缩的纳米化学治疗药物,而且还将放射性同位素固定在内部辐照热焦点处。阿霉素(DOX)和碘131标记的透明质酸(I-131-HA)被用作模型治疗剂。载有药物的PECT胶束和I-131-HA的水性混合物在体温附近表现出溶胶-凝胶转变。体外药物释放研究表明,PECT / DOX Ms可以从天然PECT / DOX MHg制剂中持续释放,而肿瘤细胞可以通过快速释放胞内DOX使其内在化。该水凝胶制剂显示出显着的体外抗肿瘤作用以及显着的放射增敏作用。体内皮下注射PECT MHg表明,I-131同位素被稳定地固定在注射部位,并且如组织病理学分析所示,未观察到对主要器官的明显损伤迹象。此外,在荷瘤裸鼠上瘤周注射包封有化学放射治疗剂的MHg制剂产生了所需的联合治疗效果,从而显着提高了肿瘤生长抑制效率,同时最大程度降低了与主要器官的药物相关副作用。因此,这样的热敏MHg制剂使得能够精确控制组合治疗剂的剂量和比例以通过单一药物施用获得所需的治疗效果并减少副作用,在时空递送多种生物活性剂以保持持续性方面具有很大的潜力。联合疗法。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号